Letter: The price of blood tests
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir, I recognise the point made by Robert Blackburn (letter, 5 December) that the patent system provides incentive for commercial research to develop marketable products that may be of value for health care. However, where the patents which result are excessively broad, this inhibits further commercial research in the area.
If broad patents are to be granted, then the liberal provision of licences by the patent holder to other manufacturers at reasonable prices is essential for optimising the development of the best possible diagnostic kits.
The reason that Murex Diagnostics' prices for anti-HCV kits were at the same general level as those of Chiron's licensees was to defray the costs of any retrospective reimbursement to Chiron for the kits that had been sold by Murex. That the price of theanti-HCV assays are at a level four times higher than for anti-HIV kits merely reflects the very high cost of the HCV licence when compared with the cost of licences for HIV.
When seen against this background, is it not reasonable to be concerned that in the absence of the pressure of wider competition provided by companies such as Murex and Organon Diagnostics, the costs of HCV kits are even less likely to fall to the more realistic levels of those of all the other viruses for which mass testing is undertaken?
Yours faithfully, JOHN BARBARA Head of Microbiology National Blood Transfusion Service London, NW9
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments